Decentralized trials offer valuable benefits, but adoption is slow, study shows

Decentralized trials offer valuable benefits, but adoption is slow, study shows


December 07, 2021

Munich, Tuesday, December 7, 2021. Software company Climedo Health has published the results of its survey on “Decentralized Clinical Trials” (DCTs). The evaluation shows that those companies working with DCTs are already experiencing numerous benefits. Those not using DCTs are mainly being held back from implementation by a lack of experience and lack of staff. 


A total of 108 companies joined the survey in the fall of 2021. Among them were mainly pharmaceutical companies, medical device manufacturers and CROs. Eighty-one percent were from Europe, while 15% were based in North America and the remainder were from Asia and Africa. The respondents’ main areas of responsibility were in Clinical Operations, Regulatory Affairs and Clinical Affairs. In terms of DCTs, two thirds had no experience with this study type so far and one third had worked with decentralized elements or even conducted DCTs on a regular basis. 


Among companies with DCT experience, Climedo Health found the following: 



Among companies without DCT experience, Climedo Health found the following: 



“We’re thrilled that so many organizations across different industries and regions joined this survey and that a third of them are actively using decentralized solutions for their trials”, says Veronika Schweighart, Co-Founder and COO of Climedo Health. “One thing that stood out to me is that 64% of the companies not using DCTs believe that we need more awareness of this study type’s benefits in order to drive adoption. In a way, this survey provides the perfect answer to this: Companies using DCTs have benefited from significant time and cost savings, improved data quality as well as improved patient and site retention. We’re also pleased that almost a third of those organizations not yet using decentralized approaches plan to do so in the coming years. It’s important to not view DCTs as an ‘all-or-nothing’ solution: Hybrid studies are very common among our respondents and can be a good way to ease into DCTs step by step. Since many companies cited a ‘lack of knowledge or experience’ in this field as a major barrier, we definitely recommend working with an experienced provider of digital solutions to get started and take traditional trials to the next level.”


The survey results can be accessed here.


PR Contact

Catherine Higginson

Senior Marketing & Communications Manager

Climedo Health GmbH